O Keefe Stevens Advisory Inc. Acquires 4,245 Shares of Pfizer Inc. $PFE

O Keefe Stevens Advisory Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 4.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,304 shares of the biopharmaceutical company’s stock after purchasing an additional 4,245 shares during the period. Pfizer makes up 0.7% of O Keefe Stevens Advisory Inc.’s portfolio, making the stock its 26th largest position. O Keefe Stevens Advisory Inc.’s holdings in Pfizer were worth $2,480,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter worth about $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter worth about $28,000. Horizon Financial Services LLC bought a new stake in shares of Pfizer in the first quarter worth about $35,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer in the first quarter worth about $35,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on PFE. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday. UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.41.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.37 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a 50 day simple moving average of $24.67 and a two-hundred day simple moving average of $24.14. The company has a market capitalization of $155.59 billion, a price-to-earnings ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.